recist
TRANSCRIPT
![Page 1: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/1.jpg)
MR3 Roberto Corrêa
14/06/2012
![Page 2: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/2.jpg)
![Page 3: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/3.jpg)
![Page 4: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/4.jpg)
![Page 5: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/5.jpg)
![Page 6: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/6.jpg)
Baseline: 4,6 + 5,4= 10,0cm.
Follow-up: 3,3 + 2,7= 6,0 cm.
Decréscimo de 40% na soma das lesões= resposta parcial.
![Page 7: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/7.jpg)
![Page 8: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/8.jpg)
![Page 9: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/9.jpg)
Homem de 64 anos com câncer de cólon
![Page 10: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/10.jpg)
Mulher de 75 anos com história de neoplasia pulmonar
![Page 11: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/11.jpg)
Mulher de 52 anos com neoplasia pulmonar
![Page 12: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/12.jpg)
Lesões não mensuráveis
![Page 13: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/13.jpg)
Mulher de 59 anos com câncer de mama
![Page 14: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/14.jpg)
Homem de 45 anos com câncer gástrico. Ascite maligna.
![Page 15: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/15.jpg)
Mulher de 70 anos com câncer de pulmão. Linfangite carcinomatosa
![Page 16: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/16.jpg)
![Page 17: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/17.jpg)
Exemplo de progressão de lesões não alvo
![Page 18: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/18.jpg)
![Page 19: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/19.jpg)
Diferença RECIST 1.0 versus 1.1
Número de lesões alvo por órgão: 2
Número total de lesões alvo: 5
Metanálise de 16 trials: não alterou resposta global; mínima influência na sobrevida livre de doença.
![Page 20: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/20.jpg)
Diferença RECIST 1.0 versus 1.1
Avaliação dos linfonodos:
Linfonodos: eixo curto ≥ 15mm: lesão mensurável (target lesion);
Linfonodos: eixo curto < 10mm: “não patológicos”;
Linfonodos: eixo curto ≥ 10mm e < 15mm: nontarget lesions;
![Page 21: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/21.jpg)
Diferença RECIST 1.0 versus 1.1
Classificação de progressão de doença:
Aumento absoluto de 5mm na soma dos diâmetros das lesões alvo e aumento de 20% dessa soma;
Essa mudança foi importante para melhor avaliar as lesões de pequeno volume.
![Page 22: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/22.jpg)
![Page 23: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/23.jpg)
Critério de CHOI:
Redução de 10% no diâmetro da lesão alvo ou;
Redução de 15% da atenuação da lesão na TC.
![Page 24: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/24.jpg)
Lesões pulmonares escavadas:
Controverso o método de mensuração.
![Page 25: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/25.jpg)
Diferença da avaliação em relação à fase do contraste
fase arterial Fase portal
![Page 26: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/26.jpg)
![Page 27: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/27.jpg)
![Page 28: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/28.jpg)
![Page 29: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/29.jpg)
![Page 30: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/30.jpg)
![Page 31: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/31.jpg)
![Page 32: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/32.jpg)
![Page 33: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/33.jpg)
![Page 34: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/34.jpg)
![Page 35: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/35.jpg)
![Page 36: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/36.jpg)
![Page 37: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/37.jpg)
![Page 38: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/38.jpg)
![Page 39: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/39.jpg)
![Page 40: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/40.jpg)
![Page 41: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/41.jpg)
![Page 42: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/42.jpg)
![Page 43: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/43.jpg)
![Page 44: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/44.jpg)
![Page 45: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/45.jpg)
Progressão de doença
![Page 46: Recist](https://reader034.vdocuments.pub/reader034/viewer/2022052619/556cb8e0d8b42ab70c8b4fed/html5/thumbnails/46.jpg)
Obrigado